



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF INFORMATION CITED BY APPLICANT (Use as many sheets as necessary)		Complete if Known					
		Application Number		10/770,117			
		Filing Date		February 2, 2004			
		First Named Inventor		Berzofsky			
		Group Art Unit		Unassigned			
Examiner Name		Unassigned					
U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
32		5,709,995	1/1998	Chisari et al.			
FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No		
32		WO 97/41440	11/06/97	Van der burg et al.			
32		WO 95/27733	10/19/95	Berzofsky et al.			
32		WO 95/12677	05/11/95	Leroux-Roels et al.			
NON-PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)					
32		Ahlers et al. "Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence," <i>Proc. Natl. Acad. Sci. USA</i> , 94:10856-10861 (September 1997)					
32		Hudrisier et al., "Relative Implication of Peptide Residues in Binding to Major Histocompatibility Complex Class I H-2Db: Application to the Design of High-Affinity, Allele-Specific Peptides," <i>Molecular Immunology</i> 32:895-907 (1995)					
32		Kalams et al., "T Cell Receptor Usage and Fine Specificity of Human Immunodeficiency Virus I-specific Cytotoxic T Lymphocyte Clones," <i>Journal of Experimental Medicine</i> 183:1669-1679 (1996)					
32		Parker et al., "Sequence motifs important for peptide binding to the human MHC class I molecule HLA-A2," <i>The Journal of Immunology</i> 149:3580-3587 (1992)					
32		Sarobe et al. "Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions," <i>J. Clin. Invest.</i> , 102(6):1239-1248 (September 1998)					
32		Shirai et al. "CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1," <i>J. Immunol.</i> , 154(6):2733-2742 (March 1995)					
Examiner Signature: <i>[Signature]</i>		Date Considered: 8/24/05					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							